Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Neogen

is $179.10 million. Neogen had $61.33 million in total cash for the latest quarter. The trailing-twelve-month revenue at Meridian Bioscience

is $169.11 million. Meridian Bioscience's PEG ratio is 1.37. The trailing-twelve-month revenue at Abaxis

is $156.60 million. Abaxis's ROE for the same period is 7.97%. The trailing-twelve-month revenue at Quidel

is $136.97 million. Quidel had $21.56 million in total cash for the latest quarter.